An Interaction between Ricin and Calreticulin That May Have Implications for Toxin Trafficking*

Philip J. DayDagger , Susan R. OwensDagger §, Jørgen Wesche||, Sjur Olsnes, Lynne M. RobertsDagger , and J. Michael LordDagger **

From the Dagger  Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom and the  Institute for Cancer Research, Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway

Received for publication, October 18, 2000, and in revised form, December 5, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here we demonstrate that ricin is able to interact with the molecular chaperone calreticulin both in vitro and in vivo. The interaction occurred with ricin holotoxin, but not with free ricin A chain; and it was prevented in the presence of lactose, suggesting that it was mediated by the lectin activity of the ricin B chain. This lectin is galactose-specific, and metabolic labeling with [3H]galactose or treating galactose oxidase-modified calreticulin with sodium [3H]borohydride indicated that Vero cell calreticulin possesses a terminally galactosylated oligosaccharide. Brefeldin A treatment indicated that the intracellular interaction occurred initially in a post-Golgi stack compartment, possibly the trans-Golgi network, whereas the reductive separation of ricin subunits occurred in an earlier part of the secretory pathway, most probably the endoplasmic reticulum (ER). Intoxicating Vero cells with ricin whose A chain had been modified to include either a tyrosine sulfation site or the sulfation site plus available N-glycosylation sites, in the presence of Na235SO4, confirmed that calreticulin interacted with endocytosed ricin that had already undergone retrograde transport to both the Golgi and the ER. Although we cannot exclude the possibility that the interaction between ricin and calreticulin is an indirect one, the data presented are consistent with the idea that calreticulin may function as a recycling carrier for retrograde transport of ricin from the Golgi to the ER.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ricin is a member of a large family of protein toxins produced by certain plants and bacteria that damage or kill mammalian cells by catalytically modifying target substrates in the cytosol (1, 2). In the case of ricin, the modification catalyzed is the removal of a specific adenine residue from a highly conserved loop present in 28 S rRNA (3). The adenine residue removed by ricin action is crucial for the binding of elongation factors, and a consequence of the toxin-mediated depurination is the cessation of protein synthesis, leading inevitably to cell death.

Structurally, ricin is a disulfide-linked heterodimer in which the rRNA N-glycosidase (termed the ricin A chain (RTA)1) is covalently joined to a galactose-specific lectin (the ricin B chain (RTB)) (4). For ricin to act, RTA must enter cells to encounter ribosomes in the cytosol. Cell entry is mediated by RTB, through which the toxin binds to cell-surface galactosides. Some of the surface-bound ricin then enters cells by endocytosis and is initially delivered to the endosomal system (5). Before endocytosed ricin can act, however, RTA must traverse an intracellular membrane to reach the ribosomes. This membrane translocation step is now known to be achieved by a proportion of the endocytosed toxin that undergoes intracellular transport beyond endosomes. Initially, the toxin is transported to the trans-Golgi network (TGN) and then, via retrograde vesicular transport through the Golgi stack, to the lumen of the ER (6). Translocation of free RTA into the cytosol from the ER possibly occurs because the toxin is perceived as a candidate for ER-associated protein degradation (7, 8). Clearly, however, a proportion of translocated RTA must escape the subsequent proteolytic degradation to then be capable of intoxicating the cell.

Electron microscopic analysis of the cellular fate of endocytosed ricin first showed that a proportion reaches the TGN (9). This raises the question of how ricin achieves retrograde transport from the TGN to the ER lumen. Several bacterial toxins also follow this trafficking route, and structural features of some of these toxins have provided an explanation of how this transport step is achieved. Pseudomonas aeruginosa exotoxin A, cholera toxin, and Escherichia coli heat-labile enterotoxin have the tetrapeptide sequence -Lys-Asp-Glu-Leu (KDEL), or a functionally related homolog, at the C terminus of the translocated catalytic polypeptide (10-12). It has been shown that cholera toxin and P. aeruginosa exotoxin A utilize the KDEL receptor, which recycles between the TGN and the ER to retrieve escaped ER lumen resident proteins from all Golgi compartments (13, 14), to undergo retrograde Golgi-to-ER transport (15, 16).

An outstanding question concerns how ricin, which lacks a C-terminal KDEL or related sequence, achieves Golgi-to-ER transport for its subsequent translocation into the cytosol? Our earlier work indicates that the lectin activity of RTB may be important in this regard (17-20). Primary sequence analysis and x-ray crystallographic studies have shown that RTB forms two distinct globular domains with identical folding topologies (17, 18). Each domain can bind a galactose residue (18). We have shown that mutationally abrogating one or other of these two galactose-binding sites does not abolish either the lectin activity of RTB or the cytotoxicity of the ricin holotoxin (19, 20). Simultaneous abrogation of both sites, however, does predictably abolish lectin activity and significantly reduces cytotoxicity (20). We have also shown that the ricin mutant unable to bind galactose did not kill macrophages, even though the mutant toxin (which was N-glycosylated) could still bind to mannose receptors and was endocytosed by these cells (20). An explanation that could account for these findings is that wild-type ricin normally has to be bound, or transferred, to a galactosylated component that itself undergoes retrograde transport, e.g. an endogenous KDEL-containing protein capable of recycling between the TGN and the ER (21). This prompted us to examine which, if any, Golgi/ER protein(s) might bind ricin holotoxin. Rat liver calreticulin is a potential candidate in that it contains a C-terminal KDEL motif and is galactosylated (22). The data presented here indicate that calreticulin interacts directly or indirectly with ricin both in vitro and in vivo. As such, it is a candidate for a Golgi-to-ER recycling cellular protein that might be opportunistically used by ricin to reach the ER lumen, an essential transport step in the entry process of this protein.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Antibodies against calreticulin, calnexin, BiP (immunoglobulin heavy chain-binding protein), and protein-disulfide isomerase were purchased from Stressgen Biotech Corp. (Victoria, British Columbia, Canada), and antibody against Rab5 was from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against RTA, RTB, and fibroblast growth factor intracellular binding protein were raised in rabbits by standard immunization. Radioisotopes were from Amersham Pharmacia Biotech (Little Chalfont, United Kingdom). Native RTA was from Inland Laboratories Inc. (Austin, TX).

Production of RTA-- Plasmids encoding RTA, RTA-sulf1 (RTA modified to include a C-terminal tyrosine sulfation site (6)), or RTA-sulf2 (RTA modified to include a tyrosine sulfation site and overlapping N-glycosylation sites at the C terminus (6)) were expressed in E. coli, and the recombinant proteins were purified to homogeneity by two rounds of CM-Sepharose chromatography and quantified as described previously (23).

Preparation of RTB-- Ricin (10 mg) in 50 mM Tris-HCl (pH 8.5), 0.1 M lactose, and 5% (v/v) beta -mercaptoethanol was stirred overnight at 4 °C. The reduced toxin was applied to a 100-ml DEAE-Sepharose column pre-equilibrated in the same buffer but containing 1% beta -mercaptoethanol and washed to remove RTA and nonreduced ricin. RTB was eluted with a linear 0-0.5 M NaCl gradient and stored at 4 °C.

Reassociation of RTA and RTB-- Equimolar mixtures of RTA (or RTA-sulf1/RTA-sulf2) and RTB were incubated in phosphate-buffered saline (PBS) containing 0.1 M lactose and 1% (v/v) beta -mercaptoethanol and dialyzed against the same buffer (without beta -mercaptoethanol) overnight and then against PBS for 2 more nights. The extent of reassociation was determined by nonreducing SDS-polyacrylamide gel electrophoresis (PAGE).

Purification of Rat Liver Microsomes-- A fresh liver from a male Harlan Sprague-Dawley rat was homogenized by passage through a 150-µm mesh sieve (24) into ice-cold 0.5 M sucrose/KM buffer (0.1 M potassium phosphate (pH 6.7) and 5 mM MgCl2), and the homogenate was adjusted to 25 ml with 0.5 M sucrose/KM buffer. Stepped sucrose gradients were prepared by successively layering 2 ml of 1.3 M sucrose/KM buffer, 4.5 ml of 0.86 M sucrose/KM buffer, 4 ml of homogenate, and 2.5 ml of 0.25 M sucrose/KM buffer. After centrifugation at 29,000 rpm in an SW 40 swing-out rotor (Beckman Instruments) for 1 h at 4 °C, the ER-enriched fraction was collected from the 0.86/1.3 M sucrose interface. After dilution to 0.5 M sucrose using KM buffer and centrifugation at 14,000 rpm for 20 min at 4 °C, microsomes were pelleted from the resulting supernatant by centrifugation at 50,000 rpm for 1 h. The pellet was resuspended in 50 mM Tris-HCl (pH 7.5), 25 mM KCl, and 5 mM MgCl2 (ER resuspension buffer) and stored in aliquots at -70 °C.

Binding of ER Components to Immobilized Ricin-- 100 µl of rat liver microsomes (containing 4.05 mg/ml protein) was solubilized by mixing with an equal volume of 1% Triton X-100 and standing at room temperature for 20 min. The sample was then applied to a 1-ml column of agarose-bound ricin (Vector Labs, Inc., Burlingame, CA) that had been equilibrated with 50 ml of ER resuspension buffer to remove stabilizing sugars. The column was washed with 10 ml of ER resuspension buffer, and 0.5-ml fractions were collected. Bound material was eluted with 5 ml of 0.1 M lactose in ER resuspension buffer and collected as a single fraction. An equal volume of ice-cold acetone was added to collected fractions, which were kept on ice for 30 min. After recovery by centrifugation at 15,000 rpm for 30 min, pellets were air-dried before being dissolved in 40 µl of ER resuspension buffer. Proteins present in each fraction were separated by SDS-PAGE, and calreticulin was visualized by enhanced chemiluminescence Western blotting (ECL detection system, Amersham Pharmacia Biotech).

Co-immunoprecipitation from ER Extracts-- 300 µl of rat liver microsomes (containing 2 mg/ml protein) was solubilized by adding an equal volume of 4% CHAPS in ER resuspension buffer and allowed to stand at room temperature for 20 min. The sample was split into four 150-µl aliquots, and 10 µg of ricin was added to each in 150 µl of ER resuspension buffer, in 150 µl of 200 mM mannose in ER resuspension buffer, in 150 µl of 200 mM lactose in ER resuspension buffer, or in 150 µl of ER resuspension buffer containing 1.5 µl of 1 M CaCl2. All samples were tumbled at room temperature for 90 min; split into three 100-µl aliquots; and immunoprecipitated with anti-calreticulin, anti-calnexin, or anti-protein-disulfide isomerase antibodies in a total volume of 1 ml of ER resuspension buffer. After tumbling at room temperature for a further 2 h, 90 µl of a 7% slurry of protein A-Sepharose was added, and tumbling was continued for a further 2 h. Protein A-Sepharose beads were recovered by centrifugation; washed four times with 50 mM HEPES-KOH (pH 7.6), 600 mM NaCl, and 1% Triton X-100; and finally resuspended in 30 µl of reducing SDS-PAGE sample buffer. Proteins were separated by SDS-PAGE and probed using a sheep antibody to ricin and ECL Western blotting.

Cell Culture-- Vero cells were propagated and maintained under standard conditions (5% CO2 in Dulbecco's modified Eagle's medium containing 5% fetal calf serum). The day prior to an experiment, the cells were seeded onto six-well plates at 3 × 105 cells/well.

Labeling Experiments-- Cells seeded as described above were either washed twice with methionine/serum-free Dulbecco's modified Eagle's medium and then incubated for 4 h in the same medium containing 25 µCi of [35S]methionine or washed twice with sulfate/serum-free minimal essential Eagle's medium for suspension cells (SMEM) (BioWhittaker UK, Ltd., Wokingham, United Kingdom) and incubated for 4 h in the presence of 200 µCi of Na235SO4. Following labeling, cells were incubated for up to 4 h in the presence of toxin. Where appropriate, cells were pretreated with brefeldin A (BFA; 10 µg/ml) for 1 h prior to adding toxin.

Calreticulin Labeling-- Vero cells were labeled by incubation for 24 h with 200 µCi of [3H]galactose. Alternatively, Vero cells were washed once with PBS and then lysed in lysis buffer supplemented with 1 mM phenylmethylsulfonyl fluoride and 200 units/ml aprotinin. The cleared lysate was incubated for 1 h with 20 units/ml galactose oxidase (Sigma). Subsequently, the lysate was incubated with 10 mCi/ml sodium [3H]borohydride. The reaction was terminated by adding 100 mM lactose and 1 mM sodium borohydride. The lysate was then immunoprecipitated using immobilized anti-calreticulin antibodies. Precipitated protein was analyzed by reducing SDS-PAGE and visualized by fluorography. A control sample was treated in the same way, but in the absence of galactose oxidase treatment.

Preparation of Cell Extracts-- Cells were washed twice with PBS containing 0.1 M lactose and then with PBS alone. Cells were lysed on ice by adding 0.5 ml of PBS containing 1% Triton X-100 and 1 mM N-ethylmaleimide. After 5 min, cells were scraped from the dishes and centrifuged to remove nuclei.

Immunoprecipitation from Cell Extracts-- Extracts were incubated with rabbit antibodies that had been immobilized on protein A-Sepharose beads at 4 °C overnight. The beads were then washed twice with PBS containing 0.1% (v/v) Triton X-100 and once with PBS alone prior to resuspension in nonreducing sample buffer and analysis by SDS-PAGE.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ricin Interacts with Calreticulin in Vitro-- The productive intoxication pathway for ricin requires retrograde transport from the TGN to the ER lumen, from where RTA translocates into the cytosol (6, 25). To achieve this retrograde trafficking, ricin possibly interacts with a cellular component(s) normally capable of recycling between the Golgi and the ER. To examine whether any Golgi/ER components could interact with ricin in vitro via the RTB lectin activity, we passed solubilized rat liver microsomal preparations down an immobilized ricin column. Since the galactose-binding activity of RTB seems to be essential for optimal ricin cytotoxicity (20, 26), any lectin-interactive components were eluted from the column with lactose. Immunoprecipitation followed by ECL Western blotting showed that the lactose eluate contained calreticulin (Fig. 1A). The lactose eluate did not contain calnexin, protein-disulfide isomerase, or BiP, but we cannot exclude the possibility that these chaperones bind to ricin in a non-lectin association. Free RTA or ricin holotoxin was next added to the microsomal extracts; calreticulin was immunoprecipitated; and any interaction between calreticulin and toxin was demonstrated by probing reducing gels of the immunoprecipitates with anti-RTA antibodies. As shown in Fig. 1B, RTA was detected only in calreticulin complexes containing ricin rather than free RTA, suggesting that the toxin was interacting with the chaperone via its B chain. The addition of either mannose or Ca2+ to the microsomal extracts did not prevent the association of toxin and calreticulin, whereas the addition of lactose did (Fig. 1C). This suggests that the association with RTB required a galactosylated oligosaccharide on calreticulin (Fig. 1C).



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Rat liver calreticulin binds to immobilized ricin. A, ER extracts were passed over an immobilized ricin-agarose column, which was then washed with ER resuspension buffer until no further protein was present in the wash fractions. Bound material was eluted from the column using 100 mM lactose in ER resuspension buffer. The presence of calreticulin was detected by SDS-PAGE and Western blotting. Lane 1, ER extract; lane 2, first collected wash fraction; lane 3, final wash (fraction 20); lane 4, lactose eluate. B, ricin (5 µg) or RTA (10 µg) was added to ER extracts, and calreticulin was recovered by immunoprecipitation. The immunoprecipitates were subjected to reducing SDS-PAGE, and coprecipitated RTA was visualized by Western blotting. Lane 1, extract supplemented with RTA; lane 2, extract supplemented with ricin. C, ricin-treated ER extracts were immunoprecipitated using anti-calreticulin antibodies, and coprecipitated RTA was visualized by Western blotting using anti-RTA antibodies as described for B, either in the absence of additives (lane 1) or in the presence of mannose (lane 2), lactose (lane 3), or calcium (lane 4).

Immunoprecipitation of Ricin from Extracts of Intoxicated Vero Cells-- Before looking for an interaction between ricin and calreticulin in vivo, we determined that we could visualize endocytosed ricin and, in particular, its reduced subunits in extracts from Vero cells treated with toxin. After incubation with toxin for the times indicated in Fig. 2, the cells were washed with 0.1 M lactose and lysed, and toxin was recovered from extracts by immunoprecipitation with either rabbit anti-RTA or anti-RTB antibodies and visualized on nonreducing gels by Western blotting using sheep anti-RTA or anti-RTB antibodies. As expected, the amount of total internalized ricin remained relatively constant over the time course due to toxin recycling between the medium and endosomes, whereas free subunits, released after intracellular cleavage within the ER or cytosol, accumulated in a time-dependent fashion. The relative accumulation rates for free RTA (Fig. 2A) and RTB (Fig. 2B) were approximately equal, suggesting that neither subunit was rapidly degraded following release from holotoxin or that both subunits were degraded to similar extents. The time course for the appearance of reduced toxin was consistent with the observed time course for cytotoxicity at the ricin concentration used, which showed that protein synthesis was significantly inhibited within 30 min and was almost abolished by 60 min (data not shown).



View larger version (68K):
[in this window]
[in a new window]
 
Fig. 2.   Appearance of free ricin subunits in cells endocytosing the toxin. Vero cells were incubated with ricin (10 µg/ml) for various times before being washed twice with PBS containing 100 mM lactose and once with PBS alone. After lysing with Triton X-100, cleared lysates were treated with antibodies to RTA (A) or RTB (B). Precipitated proteins were separated by nonreducing SDS-PAGE. Cells were harvested immediately after the addition of ricin or after the times indicated.

Accumulation of Free Toxin Subunits Can Be Prevented by Preincubation of Cells with Brefeldin A-- Ricin toxicity is abolished by preincubating cells with BFA (27, 28) presumably by preventing passage of ricin through the Golgi stack to the ER, the site of toxin entry into the cytosol. Preincubation with BFA also blocks the sulfation of ricin containing an A chain with an introduced tyrosine sulfation site (designated RCA-sulf1 (6)), a modification that is trans-Golgi-specific (29). In the proposed model for cellular intoxication by ricin, the lectin activity of RTB is required for efficient retrograde transport of holotoxin to the ER (21). Hence, it would be expected that that the reductive separation of RTA and RTB would also be prevented by BFA treatment. Cells were intoxicated with ricin for 2 h in the presence or absence of BFA, and extracts were immunoprecipitated using either anti-RTA or anti-RTB antibodies. Fig. 3 shows that preincubation with BFA had only a small effect (typically a 15% reduction) on the total amount of ricin internalized, but almost completely abolished the appearance of the free toxin subunits, suggesting that reduction normally occurs in an early (pre-TGN) compartment of the secretory pathway such as the endoplasmic reticulum. This is consistent with the earlier observation that some of the RTA-sulf2 in ricin holotoxin (RTA-sulf2 is the ricin A chain modified to have overlapping N-glycosylation sites at the C terminus (6)), as well as reduced RTA-sulf2, becomes N-glycosylated during cell entry (6). This shows that endocytosed ricin can reach oligosaccharyltransferase in the ER.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Brefeldin A treatment prevents the release of free ricin subunits. Vero cells were preincubated in the presence (+) or absence (-) of 10 µg/ml BFA for 1 h prior to being incubated with ricin for a further 2 h and subsequently treated exactly as described in the legend to Fig. 2. alpha A and alpha B indicate immunoprecipitation with anti-RTA and anti-RTB antibodies, respectively.

Ricin Interacts with Calreticulin in Vivo-- It has been proposed that the retrograde transport of ricin from the Golgi to the ER might be mediated, at least in part, by the KDEL retrieval system (21). This model proposed that ricin might bind to a recycling KDEL-tagged glycoprotein because of the lectin activity of RTB, allowing ricin to "hitch a lift" to the ER as the KDEL protein is retrieved by KDEL receptors. Candidates for such a carrier include the abundant chaperones of the ER, several of which have putative N-glycosylation sites (Grp94, calreticulin, calnexin, protein-disulfide isomerase, etc.). Vero cells were intoxicated with ricin and lysed in the presence of Triton X-100, and the lysates were immunoprecipitated with selected anti-chaperone antibodies. Immunoprecipitated proteins were analyzed by Western blotting using anti-RTA antibodies (Fig. 4A). Controls showed that ricin was immunoprecipitated by either anti-RTA or anti-RTB antibodies, but not by irrelevant antibodies (anti-Rab5). As expected, a small amount of free RTA was also precipitated by anti-RTA antibodies. Anti-calreticulin antibodies also coprecipitated ricin (but not free RTA), but no toxin was seen in complexes using antibodies against calnexin or protein-disulfide isomerase (Fig. 4A) or BiP (data not shown). Coprecipitation of ricin with calreticulin was prevented in the presence of 0.1 M lactose, which had little or no effect on the direct immunoprecipitation of ricin with either anti-RTA or anti-RTB antibodies (Fig. 4B). This observation is consistent with earlier findings that RTB plays an intracellular role during the intoxication process, in addition to its initial role in binding holotoxin to the target cell surface (20).



View larger version (55K):
[in this window]
[in a new window]
 
Fig. 4.   Ricin specifically coprecipitates with calreticulin. A and B, Vero cells were incubated with ricin for 4 h, washed, and lysed as described in the legend to Fig. 2 and treated with a range of immobilized antibodies in the absence (A) or presence (B) of 100 mM lactose. Precipitated proteins were separated by nonreducing SDS-PAGE and visualized by Western blotting using sheep anti-RTA antibodies. alpha A, anti-RTA antibody; alpha B, anti-RTB antibody; alpha CNX, anti-calnexin antibody; alpha CRT, anti-calreticulin antibody; alpha Rab, anti-Rab5 antibody; alpha PDI, anti-protein-disulfide isomerase antibody. In A and B, the upper arrows indicate ricin, and the lower arrows indicate RTA.

In keeping with this, Vero cells were treated with either free recombinant or native (glycosylated) RTA (which enters via fluid-phase uptake (30)) or free RTB for 4 h, washed, and then homogenized. Anti-RTA or anti-RTB antibodies precipitated the appropriate intracellular toxin subunit, whereas only RTB coprecipitated when calreticulin was precipitated with anti-calreticulin antibodies (Fig. 5). Although equal concentrations of RTA and RTB were added to cells, the relative amounts of RTA and RTB precipitated predictably confirmed that the cellular uptake of RTB was much more efficient. This is because uptake of RTB is receptor-mediated, whereas free A chains enter cells in the fluid phase.



View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   RTB coprecipitates with calreticulin. Vero cells were incubated with 5 µg of glycosylated RTA (gRTA; lanes 1 and 2), recombinant RTA (rRTA; lanes 3 and 4), or RTB (lanes 5 and 6) for 4 h prior to washing and lysis in Triton X-100. Cleared lysates were treated with immobilized antibodies, and the precipitated proteins were analyzed by SDS-PAGE. Lanes 1 and 3, anti-RTA antibody (alpha A); lane 5, anti-RTB antibody (alpha B); lanes 2, 4, and 6, anti-calreticulin antibody (alpha CRT).

To test that calreticulin was able to interact with ricin that had already been transported to the Golgi complex, where tyrosylsulfotransferase is found, the coprecipitation experiment was repeated, but using cells that had been intoxicated with ricin containing RTA-sulf1 (RTA that had been modified to contain a tyrosine sulfation site (6)) in the presence of Na235SO4. Fig. 6A shows that 35S-labeled ricin holotoxin was immunoprecipitated by anti-RTA, anti-RTB, or anti-calreticulin antibodies and that the interaction was again abolished in the presence of lactose.



View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Calreticulin binds to ricin that has reached the Golgi complex and the ER. A, Vero cells were labeled with Na235SO4 for 4 h prior to the addition of ricin containing RTA-sulf1. After incubation for a further 4 h, cells were washed, lysed, and immunoprecipitated with anti-RTA (alpha A), anti-RTB (alpha B), or anti-calreticulin (alpha CRT) antibodies in the absence or presence of 100 mM lactose. Precipitated proteins were analyzed by nonreducing SDS-PAGE and visualized by fluorography. The upper arrow indicates 35S-sulfated ricin, and the lower arrow indicates 35S-sulfated RTA. B, the same experiment was repeated, but using reconstituted ricin containing RTA-sulf2. In this case, precipitated proteins were analyzed by reducing SDS-PAGE. alpha CNX, anti-calnexin antibody; gA and A, glycosylated RTA and non-glycosylated RTA, respectively.

To test that calreticulin remained in contact with ricin until it reached the ER (the location of oligosaccharyltransferase), coprecipitations were also performed using extracts from cells that had been intoxicated with ricin containing RTA-sulf2 (a recombinant RTA modified to contain overlapping C-terminal N-glycosylation sites (6)) in the presence of Na235SO4. Fig. 6B shows that immunoprecipitation with either anti-calreticulin or anti-ricin antibodies yielded both non-glycosylated RTA and newly glycosylated RTA (6). (To clearly see the gel mobility difference between RTA and glycosylated RTA, reducing SDS-PAGE was used in this case.) Significantly less RTA or glycosylated RTA was precipitated by anti-calnexin antibodies, but the data shown in Fig. 6B indicate that limited interaction with calnexin may also have occurred.

To ensure that the interaction between calreticulin and ricin was not simply due to post-lysis binding events, time course experiments were performed. The amount of ricin internalized remained reasonably constant over a 4-h time course (see Fig. 2). In contrast, the amount of internalized ricin that co-immunoprecipitated with calreticulin increased steadily over the first 2 h and then remained relatively constant for the remaining 2 h of the assay (Fig. 7A), perhaps suggesting that a steady state had been reached. It would be expected that BFA pretreatment would also reduce any specific interaction between ricin and calreticulin since it would prevent recycling between the ER and the Golgi complex. Fig. 7B shows that BFA treatment did significantly reduce (by ~75%) the co-immunoprecipitation of ricin with calreticulin, whereas it had only a small effect on the amount of ricin internalized (~15% reduction) (Fig. 3).



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Brefeldin A reduces the coprecipitation of ricin with calreticulin. A, Vero cells were intoxicated with ricin for the indicated times, washed, lysed, and immunoprecipitated with immobilized anti-calreticulin antibodies. Immunoprecipitates were analyzed by nonreducing SDS-PAGE and visualized by Western blotting using anti-RTA antibodies. B, Vero cells were incubated in the presence (+) or absence (-) of BFA (10 µg/ml) for 1 h prior to the addition of ricin and incubation for a further 2 h. Cells were washed, lysed, immunoprecipitated, and analyzed as described for A.

To further demonstrate a specific interaction between calreticulin and ricin, it was important to show that immunoprecipitates of ricin from intoxicated cells also coprecipitated calreticulin. Vero cells were metabolically labeled with [35S]methionine for 4 h prior to intoxication with ricin for a further 4 h. Lysates were immunoprecipitated with anti-RTA, anti-RTB, or anti-calreticulin antibodies; the pellets were washed and boiled in 1% SDS; and samples were diluted and re-immunoprecipitated with anti-calreticulin antibodies. Fig. 8 shows that in the absence of toxin treatment, calreticulin was precipitated only when the primary antibody was anti-calreticulin. In contrast, when cells had been intoxicated with ricin, calreticulin could be precipitated by both anti-RTA and anti-RTB antisera (Fig. 8).



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 8.   Calreticulin coprecipitates with ricin. Vero cells were labeled with [35S]methionine (25 µCi) for 4 h and then incubated for a further 4 h in the absence (-) or presence (+) of ricin. Following washing and lysis, cleared extracts were immunoprecipitated with the appropriate primary antibody as indicated. Immunoprecipitates were washed twice with PBS and 0.1% Triton X-100 and once with PBS alone prior to being resuspended in 100 µl of PBS and 1% SDS and boiled for 2 min. The denatured extracts were diluted to 1 ml with PBS and 0.5% Triton X-100, and the protein A-Sepharose beads were removed by centrifugation. Extracts were all subsequently immunoprecipitated using anti-calreticulin antibodies, and precipitated protein was analyzed by SDS-PAGE and visualized by fluorography. alpha CRT, anti-calreticulin antibody; alpha A, anti-RTA antibody; alpha B, anti-RTB antibody.

Calreticulin from Vero Cells Is a Galactose-containing Glycoprotein-- The interaction between ricin and calreticulin described here is mediated by the toxin B chain and is prevented by lactose. This requires that Vero cell calreticulin is glycosylated and that the glycosyl moiety contains terminal galactosyl residues. Vero cells were therefore incubated with [3H]galactose for 24 h prior to immunoprecipitation of lysates with anti-calreticulin antibodies. Fig. 9A shows that [3H]galactose was incorporated into calreticulin.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 9.   Vero cell calreticulin is galactosylated. A, Vero cells were labeled for 24 h with [3H]galactose (200 µCi) or for 8 h with [35S]methionine (25 µCi) and lysed with Triton X-100, and cleared extracts were immunoprecipitated with immobilized anti-calreticulin antibodies. Precipitated proteins were analyzed by SDS-PAGE and fluorography. Lane 1, [35S]methionine-labeled cells; lane 2, molecular weight markers; lane 3, [3H]galactose-labeled cells. The arrow indicates the calreticulin (CRT) band. B, Vero cell lysates were first treated with galactose oxidase (20 units/ml) and then with sodium [3H]borohydride (10 mCi/ml). The reactions were terminated by the addition of 100 mM lactose and 1 mM sodium borohydride. Immobilized antibodies were subsequently added to the lysates, and precipitated proteins were analyzed by SDS-PAGE and fluorography. Lane 1, anti-calreticulin antibody (alpha CRT); lane 2, anti-fibroblast growth factor intracellular binding protein antibody (alpha FIBP); lane 3, anti-RTA antibody (alpha RTA); lane 4, calreticulin immunoprecipitated from [35S]methionine-labeled cells. C, the same experiment as described for B was carried out, but with (lane 2) or without (lane 3) galactose oxidase treatment. Lane 1, calreticulin immunoprecipitated from [35S]methionine-labeled cells.

It could not be excluded, however, that the [3H]galactose was being metabolized in the cells and that 3H was being incorporated into calreticulin in another form. To test further if Vero cell calreticulin is galactosylated, we took advantage of a biochemical assay to selectively label proteins with terminal galactose (31). Proteins present in a Vero cell homogenate were treated with the enzyme galactose oxidase and then with sodium [3H]borohydride to bind any oxidized terminal galactose residues. Immunoprecipitation with anti-calreticulin antibodies showed that a band corresponding in molecular mass to calreticulin was labeled after such treatment (Fig. 9B, lane 1). This band was not obtained in immunoprecipitates with antibodies against fibroblast growth factor intracellular binding protein (Fig. 9B, lane 2) or ricin (lane 3) or in the absence of galactose oxidase treatment (Fig. 9C). For comparison, Vero cells labeled with [35S]methionine were lysed and subjected to immunoprecipitation with anti-calreticulin antibodies. The [35S]methionine-labeled calreticulin seen in lane 4 of Fig. 9B had the same migration rate as the [3H]borohydride band in lane 1. The other bands seen in lane 1-3 could be due to labeling of the polyclonal rabbit antibodies used or other galactosylated proteins that nonspecifically interact with the antibodies. Taken together, the data indicate that at least a fraction of the calreticulin expressed in Vero cells contains a terminal galactose residue.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The data presented here show that ricin can interact with calreticulin in vitro and in vivo. Interaction in vivo did not appear to be an artifact caused by homogenizing the cells since (i) the level of interaction was shown to increase with time over a period when the total intracellular ricin pool did not alter significantly and (ii) BFA treatment of cells significantly reduced the extent of this interaction without significantly affecting ricin uptake.

The interaction could take one of several forms, although a direct protein-protein interaction is unlikely because of its lactose-dependent nature. An interaction of the sugar-binding site of calreticulin with glucose residues present on RTA and/or RTB is also unlikely since the glycans present on native RTA are complex and endoglycosidase H-resistant (32). Also, since both toxin subunits have undergone ER-to-vacuole transport with associated Golgi processing of their glycans in the producing plant (33), the toxin subunits are not monoglucosylated, a requirement for any interaction with the sugar-binding site of calreticulin. Furthermore, the interaction we observed involves native ricin, whereas calreticulin is known to interact with partially folded proteins. This, together with the data presented here, supports an interaction between the galactose-specific binding sites of RTB and galactosyl groups present on calreticulin. This contention is further supported by the facts that calreticulin interacts with ricin, but not free RTA, indicating that the association occurs via RTB, and that the interaction is abolished in the presence of lactose, which is known to block the biological activity of the RTB lectin.

An interaction mediated by the sugar-binding sites of RTB would require that calreticulin is glycosylated and that the oligosaccharide contains a terminal galactose residue. Until recently, the glycosylation status of calreticulin has been unclear. Although the primary sequences of calreticulin isolated from several different species all contain a single putative N-glycosylation site, the search for an attached glycan has been inconclusive. Calreticulins from rat liver (34) and bovine liver (35) are known to be glycosylated; but in most species, including human, calreticulin was thought to be non-glycosylated (36). More recently, however, calreticulin from human myeloid cells has been shown to be glycosylated, despite the fact that neither tunicamycin treatment of the cells nor endoglycosidase digestion of calreticulin had any effect on the protein's mobility on SDS-polyacrylamide gels (37). Since human glycosylated calreticulin has the apparent properties of a non-glycosylated protein, it is possible that other forms are also glycosylated, despite reports to the contrary. Here we were able to metabolically label calreticulin from Vero cells with [3H]galactose and confirm that Vero cell calreticulin contains an oligosaccharide with a terminal galactose residue by treatment with galactose oxidase followed by sodium [3H]borohydride, providing an explanation for its apparent ability to interact with RTB.

Calreticulin contains an N-terminal signal sequence and a C-terminal ER retrieval sequence (KDEL); and as expected, its major intracellular location is the lumen of the ER (36, 38). Calreticulin has been reported to be present in other cellular locations, however, including later compartments of the secretory pathway (39) and at the cell surface (40). It is tempting to suggest that the interaction between ricin and calreticulin that occurs in vivo is physiologically significant in that calreticulin functions as a retrograde carrier that transports ricin from the TGN to the ER. Although the present data do not provide unequivocal evidence for such a function, several features of the interaction are consistent with this idea. To act as a retrograde carrier, calreticulin would normally need to recycle between the ER and the trans-Golgi. This certainly seems to be the case for rat liver calreticulin since it is terminally galactosylated (22), a modification that occurs in the trans-Golgi cisternae (41). Likewise, we have shown here that Vero cell calreticulin is galactosylated, a feature that would allow its interaction with the RTB subunit of incoming ricin. The finding that BFA pretreatment of cells (to disrupt the Golgi stack, but not the TGN), significantly reduced, but did not abolish, the calreticulin-ricin interaction is also consistent with the TGN or a later secretory pathway compartment being the site where the interaction initially occurs. This supports the idea that a ricin-calreticulin interaction can occur before ricin reaches the ER rather than after it reaches this compartment and suggests that its primary purpose is the delivery of toxin to the ER rather than any subsequent events. The interaction in vivo is stable, and the fact that it does not involve free RTA implies that what we are seeing does not reflect events within the ER leading to membrane translocation where association with chaperones may be very transient and involve the translocating RTA subunit. By virtue of its C-terminal ER retrieval sequence, any calreticulin present in the TGN and interacting there with incoming ricin could predictably be recycled to the ER lumen via KDEL receptors. These receptors are known to recycle between the ER and the Golgi (13) and can retrieve proteins to the ER from the trans-most cisterna of the Golgi complex (14). In keeping with this, we have shown that overexpressing lysozyme-KDEL, which causes a relocation of the KDEL receptor from the Golgi complex to the ER (42), reduced the sensitivity of cells to ricin intoxication.2 This implies that ricin, at least in part, might indirectly utilize the KDEL retrieval system to undergo Golgi-to-ER retrograde transport. Because ricin is a galactose-specific lectin, it could presumably bind any appropriate galactosylated glycoprotein or glycolipid it might encounter intracellularly; and if any of these were to recycle between the TGN and the ER, they could potentially be parasitized by ricin for retrograde transport. However, it must be stressed that much of the data presented here could be explained by an indirect interaction between ricin and calreticulin, and we concede that the physiological significance of the interaction during toxin entry remains speculative. In any event, calreticulin is unlikely to be the exclusive carrier for ricin. Indeed, calreticulin-deficient cell lines remain sensitive to ricin (data not shown). We suggest that calreticulin is one of a number of as yet unidentified cellular components that can act in this way and that retrieval systems other than that involving the KDEL receptor may likewise be utilized. Calreticulin may be the preferred carrier, however, since if it enters the ER lumen in association with ricin, it would be well placed to guide toxin unfolding and/or some other event required for the subsequent RTA translocation across the ER membrane.


    FOOTNOTES

* This work carried out at the University of Warwick was supported by Grant BO8000 from the United Kingdom Bio/Technology and Biological Sciences Research Council and the Wellcome Trust, and that at the Norwegian Radium Hospital was supported by the Norwegian Cancer Society, the Novo Nordisk Foundation, the Norwegian Research Council, the Blix Fund for the Promotion of Medical Research, Rachel and Otto Kr. Brunn's Legat, and by the Jahre Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: European Molecular Biology Laboratory, Heidelberg 69117, Germany.

|| Fellow of the Norwegian Cancer Society.

** To whom correspondence should be addressed. Tel.: 44-24-7652-3598; Fax: 44-24-7652-3701; E-mail: Mike.Lord@warwick.ac.uk.

Published, JBC Papers in Press, December 11, 2000, DOI 10.1074/jbc.M009499200

2 M. E. Jackson, L. M. Roberts, and J. M. Lord, unpublished data.


    ABBREVIATIONS

The abbreviations used are: RTA, ricin A chain; RTB, ricin B chain; TGN, trans-Golgi network; ER, endoplasmic reticulum; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; BFA, brefeldin A.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Olsnes, S., Kozlov, J. V., van Deurs, B., and Sandvig, K. (1991) Semin. Cell Biol. 2, 7-14[Medline] [Order article via Infotrieve]
2. Lord, J. M., Hartley, M. R., and Roberts, L. M. (1991) Semin. Cell Biol. 2, 15-22[Medline] [Order article via Infotrieve]
3. Endo, Y., Mitsui, K., Motizuki, M., and Tsurugi, K. (1987) J. Biol. Chem. 262, 5908-5912[Abstract/Free Full Text]
4. Olsnes, S., and Pihl, A. (1973) Biochemistry 12, 3121-3126[Medline] [Order article via Infotrieve]
5. van Deurs, B., Pederson, O. W., Sundan, A., Olsnes, S., and Sandvig, K. (1985) Exp. Cell Res. 159, 287-304[Medline] [Order article via Infotrieve]
6. Rapak, A., Falnes, P. O., and Olsnes, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3783-3788[Abstract/Free Full Text]
7. Simpson, J. C., Roberts, L. M., Römisch, K., Davey, J., Wolf, D. H., and Lord, J. M. (1999) FEBS Lett. 459, 80-84[CrossRef][Medline] [Order article via Infotrieve]
8. Wesche, J., Rapak, A., and Olsnes, S. (1999) J. Biol. Chem. 274, 34443-34449[Abstract/Free Full Text]
9. van Deurs, B., Tonnessen, T. O., Pererson, O. W., Sandvig, K., and Olsnes, S. (1986) J. Cell Biol. 102, 37-47[Abstract]
10. Gray, G. L., Smith, D. H., Baldridge, J. S., Harkins, R. N., Vasil, M. L., Chen, E. Y., and Heyneker, H. L. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 2645-2649[Abstract]
11. Mekalanos, J. J., Swarth, D. J., Pearson, G. D. N., Harford, N., and Groyne, F. (1980) Nature 306, 551-557
12. Spicer, E. K., and Noble, J. A. (1982) J. Biol. Chem. 257, 5716-5721[Abstract/Free Full Text]
13. Pelham, H. R. B. (1991) Curr. Opin. Cell Biol. 3, 585-591[Medline] [Order article via Infotrieve]
14. Miesenbock, G., and Rothman, J. E. (1995) J. Cell Biol. 129, 309-319[Abstract]
15. Majoul, I., Sohn, K., Wieland, F. T., Pepperkok, R., Pizza, M., Hillemann, J., and Söling, H.-D. (1998) J. Cell Biol. 143, 601-612[Abstract/Free Full Text]
16. Jackson, M. E., Simpson, J. C., Girod, A., Pepperkok, R., Roberts, L. M., and Lord, J. M. (1999) J. Cell Sci. 112, 467-475[Abstract/Free Full Text]
17. Villafranca, J. E., and Robertus, J. D. (1981) J. Biol. Chem. 256, 554-556[Abstract/Free Full Text]
18. Montfort, W., Villafranca, J. E., Monzingo, A. F., Ernst, S. R., Katzin, B., Rutenber, E., Xuong, N. H., Hamil, R., and Robertus, J. D. (1987) J. Biol. Chem. 262, 5398-5403[Abstract/Free Full Text]
19. Wales, R., Richardson, P. T., Roberts, L. M., Woodland, H. R., and Lord, J. M. (1991) J. Biol. Chem. 266, 19172-19179[Abstract/Free Full Text]
20. Newton, D. L., Wales, R., Richardson, P. T., Wallbridge, S., Saxena, S. E., Ackerman, E. J., Roberts, L. M., Lord, J. M., and Youle, R. J. (1992) J. Biol. Chem. 267, 11917-11922[Abstract/Free Full Text]
21. Pelham, H. R. B., Roberts, L. M., and Lord, J. M. (1992) Trends Cell Biol. 2, 183-185[Medline] [Order article via Infotrieve]
22. Peter, F., Van, N. P., and Söling, H.-D. (1992) J. Biol. Chem. 267, 10631-10637[Abstract/Free Full Text]
23. Wales, R., Chaddock, J. A., Roberts, L. M., and Lord, J. M. (1992) Exp. Cell Res. 203, 1-4[Medline] [Order article via Infotrieve]
24. Hino, Y., Asano, A., Sato, R., and Shimizu, S. (1978) J. Biochem. (Tokyo) 83, 909-923[Abstract]
25. Lord, J. M., and Roberts, L. M. (1998) J. Cell Biol. 140, 733-736[Free Full Text]
26. Youle, R. J., Murray, G. J., and Neville, D. M., Jr. (1981) Cell 23, 551-559[Medline] [Order article via Infotrieve]
27. Sandvig, K., Prydz, K., Hansen, S. H., and van Deurs, B. (1991) J. Cell Biol. 115, 971-981[Abstract]
28. Yoshida, T., Chen, C., Zhang, M., and Wu, H. C. (1991) Exp. Cell Res. 192, 389-395[Medline] [Order article via Infotrieve]
29. Rosa, P., Mantovani, S., Rosboch, R., and Huttner, W. B. (1992) J. Biol. Chem. 267, 12227-12232[Abstract/Free Full Text]
30. Sandvig, K., and van Deurs, B. (1990) J. Biol. Chem. 265, 6382-6388[Abstract/Free Full Text]
31. Gahmberg, C. T., and Hakomori, S. I. (1973) J. Biol. Chem. 248, 4311-4317[Abstract/Free Full Text]
32. Lord, J. M., and Harley, S. M. (1985) FEBS Lett. 189, 72-76[CrossRef]
33. Lord, J. M. (1985) Eur. J. Biochem. 146, 411-416[Abstract]
34. Van, P. N., Peter, F., and Söling, H.-D. (1989) J. Biol. Chem. 264, 17494-17501[Abstract/Free Full Text]
35. Waisman, D., Salmath, B. P., and Anderson, M. I. (1985) J. Biol. Chem. 260, 1654-1660
36. Michalak, M., Milner, R. E., Burns, K., and Opas, M. (1992) Biochem. J. 285, 681-692[Medline] [Order article via Infotrieve]
37. Denning, G. M., Leidal, K. G., Holst, V. A., Iyer, S. S., Pearson, D. W., Clark, J. R., Nauseef, W. M., and Clark, R. A. (1997) Blood 90, 372-381[Abstract/Free Full Text]
38. Michalak, M., Corbett, E. F., Mesaeli, N., Nakamura, K., and Opas, M. (1999) Biochem. J. 344, 281-292[CrossRef][Medline] [Order article via Infotrieve]
39. Dupius, M., Schaerer, E., Krause, K.-H., and Tschlopp, J. (1993) J. Exp. Med. 177, 1-7[Abstract]
40. White, T. K., Zhu, Q., and Tanzer, M. L. (1995) J. Biol. Chem. 270, 15926-15929[Abstract/Free Full Text]
41. Kornfeld, R., and Kornfeld, S. (1985) Annu. Rev. Biochem. 54, 631-664[CrossRef][Medline] [Order article via Infotrieve]
42. Lewis, M. J., and Pelham, H. R. B. (1992) Cell 68, 353-364[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.